| 词条 | Immunocore |
| 释义 |
| name = Immunocore | logo = File:Logo_of_Immunocore.gif | logo_size = 250px | logo_padding = | logo_alt = | logo_caption = | image = | image_size = | image_alt = | image_caption = | native_name = | native_name_lang = | former_name = | type = Private | industry = Biotechnology | founded = {{start date|2008}} in Oxford, England | founders = Dr. Bent Jakobsen and James Noble | hq_location = | hq_location_city = | hq_location_country = | area_served = | key_people = Andrew Hotchkiss, CEO; Jonathan Knowles, Chairman; Nicholas Cross, Deputy Chairman of the Board; Eva-Lotta Allan, Chief Business Officer | products = Cancer drugs/treatments using T-Cell receptor technology | brands = | services = | owner = | website = {{URL|http://www.immunocore.com/}} }} Immunocore is a privately owned British clinical-stage biotechnology company,[1] based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor (TCR) technology. HistoryImmunocore was founded in 2008 as a spinout of German Medigene AG who had acquired former Avidex in 2006 (founded in 1999 as a spinout from the University of Oxford by Dr Bent Jakobsen)and CEO James Noble [1] In July 2013 GlaxoSmithKline paid ₤142 million for the rights to pre-clinical drugs they had developed which act against several targets that Immunocore had been working on.[2] GlaxoSmithKline has to date selected three targets as part of this discovery collaboration. The lead programme with GSK is on track for an Investigational New Drug (IND) application in 2017 with potential application in Non-Small Cell Lung Cancer (NSCLC), bladder cancer, synocial sarcoma, melanoma and ovarian cancer.[3] In June 2013 Immunocore entered into a similar deal with Genentech, which, according to the deal, would earn Immunocore an initiation fee of between $10 million and $20 million for each lead programme initiated by Genentech and in excess of $300 million in milestone payments for each target programme and significant tiered royalties.[4] In January 2014, MedImmune - the global biologics research and development arm of AstraZeneca announced the next oncology research collaboration and licensing agreement for Immunocore; an upfront payment of $20 million and up to $300 million in development and commercial milestone payments for each target programme selected as well as significant tiered royalties if these programmes were successful. In July 2015, Immunocore announced the completion of a $320 million private financing round.[5] Fidelity Management & Research Company, Woodford Investment Management, Malin Corporation, Eli Lilly and Company, and RTW Investments all participated in this fundraise along with other unnamed investors and existing shareholders. In September 2017, the Bill & Melinda Gates Foundation announced that they would invest up to $40 million to support the development of Immunocore's soluble TCR-based therapeutics for infectious diseases.[6] The collaboration was set up to discover and develop ImmTAV® (Immune mobilising monoclonal TCRs Against Virus) and ImmTAB™ (Immune mobilising monoclonal TCRs Against Bacteria) molecules for the treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) [7] where the TCR-based therapeutics have the potential to reduce treatment timelines and improve patient outcomes. This partnership is part of a larger initiative within Immunocore to apply its soluble TCR-based therapeutics to areas outside of oncology, including infectious diseases and autoimmune diseases.[8] Scientific backgroundTCRs are molecules found on the surface of T lymphocytes (or T cells) and play various roles in the immune system. TCRs are often cited as aiding in recognising foreign antigens being presented by cells which have been infected by viruses or intracellular bacteria. Immunocore has developed a line of biologic medicines by combining engineered, cancer-recognising, soluble TCRs with immune activating complexes, which, in theory, creates a drug that directs the immune system to kill cancer cells. These drugs are commonly referred to as immune-mobilising monoclonal TCRs against cancer (ImmTAC molecules).[9] Immunocore's TCR technology has a broad applicability to a wide range of intracellular targets and disease indications including solid tumours, infectious diseases and autoimmune diseases.[10] Clinical pipelineIMCgp100Immunocore's wholly owned lead programme, IMCgp100,[11] is an immunotherapy for metastatic uveal and cutaneous melanoma and is currently in a pivotal clinical study as a monotherapy for the treatment of patients with metastatic uveal melanomas.[12] Immunocore has also entered into combination trials with IMCgp100 in metastatic cutaneous melanoma with MedImmune (AstraZeneca)[13] and in metastatic uveal melanoma with Lilly.[14] IMCgp100 was granted orphan drug designation for the treatment of uveal melanoma by the US Food and Drug Administration (FDA) in 2016. Corporate governanceThe inaugural chairman of Immunocore's board of directors was Nicholas Cross.[16] In late 2013, Jonathan Knowles succeeded Cross in this position, and Cross was retained as deputy chairman.[16] Knowles had previously served as a non-executive director since 2010.[15] Eliot Forster served as chief executive officer (CEO)[16] of Immunocore from February 2015 to February 2018. The current CEO is Andrew Hotchkiss,[17] who previously served as Chief Commercial Officer (CCO) at Immunocore. See also
References1. ^1 {{Cite web|url=http://www.immunocore.com|title=Transformational Science that Transforms Lives - Immunocore|website=www.immunocore.com|language=en|access-date=2017-11-10}} 2. ^{{cite news |title=GSK taps UK firm for "beyond antibodies" cancer drug technology|url=http://www.foxnews.com/health/2013/07/09/gsk-taps-uk-firm-for-beyond-antibodies-drug-technology/|newspaper=Fox News Channel|date=9 July 2013|accessdate=9 July 2013}} 3. ^{{Cite web|url=http://www.immunocore.com/news/2017/07/immunocore-announces-third-oncology-target-selected-in-discovery-collaboration-with-glaxosmithkline|title=Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline {{!}} News - Immunocore|website=www.immunocore.com|language=en|access-date=2017-11-10}} 4. ^{{Cite web|url=https://www.genengnews.com/gen-news-highlights/genentech-makes-potentially-300m-pact-for-immunocore-s-immtacs/81248534/|title=Genentech Makes Potentially $300M+ Pact for Immunocore's ImmTACs {{!}} GEN|website=GEN|access-date=2017-11-10}} 5. ^{{Cite news|url=http://uk.reuters.com/article/uk-immunocore-investment/immunocore-raises-320-million-in-record-financing-round-idUKKCN0PQ0DS20150716|title=Immunocore raises $320 million in record financing round|last=Halpin|first=Padraic|work=U.K.|access-date=2017-11-10|language=en-GB}} 6. ^{{Cite news|url=https://gmpnews.net/2017/09/gates-foundation-invests-40-million-in-immunocores-efforts/|title=Gates Foundation invests $40 million in Immunocore's efforts|last=andrewvolkoff|date=2017-09-18|work=GMP news|access-date=2017-11-10|language=en-US}} 7. ^{{Cite news|url=https://labiotech.eu/immunocore-bill-gates-immunotherapies/|title=British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation|date=2017-09-18|work=Labiotech.eu|access-date=2017-11-10|language=en-US}} 8. ^{{Cite news|url=http://www.pharmaceutical-technology.com/news/newsimmunocore-receives-funding-to-develop-immtav-and-immtab-therapeutics-for-infectious-diseases-5927937/|title=Gates Foundation supports development of Immunocore’s therapeutics for infectious diseases - Pharmaceutical Technology|date=2017-09-18|work=Pharmaceutical Technology|access-date=2017-11-10|language=en-GB}} 9. ^{{Cite journal|last=Liddy|first=Nathaniel|last2=Bossi|first2=Giovanna|last3=Adams|first3=Katherine J|last4=Lissina|first4=Anna|last5=Mahon|first5=Tara M|last6=Hassan|first6=Namir J|last7=Gavarret|first7=Jessie|last8=Bianchi|first8=Frayne C|last9=Pumphrey|first9=Nicholas J|date=2012-05-06|title=Monoclonal TCR-redirected tumor cell killing|journal=Nature Medicine|language=en|volume=18|issue=6|pages=980–987|doi=10.1038/nm.2764|pmid=22561687|issn=1546-170X}} 10. ^{{Cite web|url=https://www.immunocore.com/technology/targets|title=Targets - Immunocore|website=www.immunocore.com|language=en|access-date=2017-11-10}} 11. ^{{Cite news|url=https://clinicaltrials.gov/ct2/show/NCT01211262|title=Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma - Full Text View - ClinicalTrials.gov|access-date=2017-11-10|language=en}} 12. ^{{Cite news|url=http://markets.businessinsider.com/news/stocks/Immunocore-and-the-Bill-Melinda-Gates-Foundation-Collaborate-to-Develop-Immunotherapies-for-Infectious-Diseases-1002378180|title=Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases|last=GmbH|first=finanzen.net|work=markets.businessinsider.com|access-date=2017-11-10}} 13. ^{{Cite web|url=https://www.immunocore.com/news/2016/01/immunocore-starts-clinical-trial-with-imcgp100-in-combination-with-medimmune-immunotherapies-durvalumab-and-tremelimumab|title=Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab {{!}} News - Immunocore|website=www.immunocore.com|language=en|access-date=2017-11-10}} 14. ^{{Cite web|url=https://www.immunocore.com/news/2015/06/immunocore-and-lilly-announce-immunotherapy-based-clinical-trial-collaboration-in-melanoma|title=Immunocore and Lilly announce immunotherapy-based clinical trial collaboration in melanoma {{!}} News - Immunocore|website=www.immunocore.com|language=en|access-date=2017-11-10}} 15. ^1 2 {{cite news | date=December 2013 | title=BMS changes senior management team | author=Slatko, Joshua | work=Med Ad News | page=27 | department=People on the Move: Biopharma }} 16. ^{{Cite web|url=http://www.immunocore.com/news/2015/01/immunocore-appoints-dr-eliot-forster-as-chief-executive-officer|title=Immunocore appoints Dr Eliot Forster as Chief Executive Officer {{!}} News - Immunocore|website=www.immunocore.com|language=en|access-date=2017-11-10}} 17. ^{{Cite web|url=https://www.immunocore.com/news/2018/02/im|title=Immunocore Announces Leadership Change {{!}} News - Immunocore|website=www.immunocore.com|language=en|access-date=2018-02-27}} External links
5 : Immunomodulating drugs|Biotechnology companies of the United Kingdom|Pharmaceutical companies established in 2008|Biotechnology companies established in 2008|2008 establishments in the United Kingdom |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。